Company intelligence / Profile preview

PaxGenBio

Anyang-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~7
Development stage: Other

Overview

PaxGenBio is a Korean in vitro diagnostics company commercializing molecular diagnostic kits, including PaxView-branded products for COVID-19, tuberculosis/nontuberculous mycobacteria, HPV genotyping, and other infectious diseases, based on its proprietary MPCR-ULFA multiplex PCR and universal lateral flow assay platform with regulatory approvals such as KFDA clearance and ISO 13485/KGMP certifications.[2][3][4][7][10]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Device
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on PaxGenBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PaxGenBio.

Explore the full profile